AI-found target and AI-made molecule reach Phase III
Insilico announced the first patient dosed in a 52-week Phase III trial of rentosertib for idiopathic pulmonary fibrosis. It describes the drug as the first candidate with both an AI-identified target and an AI-generated molecule to reach Phase III, after positive Phase IIa results in Nature Medicine in 2025.